Volume : 09, Issue : 02, February – 2022

Title:

32.AN OVEVRIEW OF THE USE OF STATIN AND METFORMIN AMONG ELDERLY WOMEN WITH BREAST CANCER AND DIABETES

Authors :

Mohammed Saleh Ibn Abdullah Alamri, Dareen esmail abdulhamid qashqari , Muna Mohammed balgith Alzahrani, Reem Mohammed amin arshad Banjar, Ghofran Fares Hamzah Sannan, Saad mohammed awwadh alshalwi, Mohammed flaih frees alotaibi, Fahad Noor Faleh Alasadi, Mohammed Nuwaymi Toma Aljaberi , Nader Essa Subayyil Alotaibi, Ali Abdullah Ahmed Alqarni, Talal tail Alsulami

Abstract :

The inverse correlation of the malignancies evaluated with metformin usage, demonstrated even after short durations of treatment, raises the hypothesis that the primary benefit is diabetes control rather than the pharmacological activity of this specific medication. Databases reviewed for all the relevant articles in literature published up to the end of 2021. Metformin may reduce the incidence of breast cancer, according to emerging evidence, however reports are varied and few include information on tumor features. Prediagnostic statin use, on the other hand, was found to predict lower death from breast cancer and other causes.

Cite This Article:

Please cite this article in press Mohammed Saleh Ibn Abdullah Alamri et al, An Ovevriew Of The Use Of Statin And Metformin Among Elderly Women With Breast Cancer And Diabetes., Indo Am. J. P. Sci, 2022; 09(2)

Number of Downloads : 10

References:

1. Michels KB, Solomon CG, Hu FB, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care. 2003;26:1752–1758.
2. Wolf I, Sadetzki S, Catane R, et al. Diabetes mellitus and breast cancer. Lancet Oncol. 2005;6:103–111.
3. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer. 2007;121:856–862.
4. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: Duration and insulin effects. Diabetologia. 2012;55:948–958.
5. Bowker SL, Richardson K, Marra CA, et al. Risk of breast cancer after onset of type 2 diabetes: Evidence of detection bias in postmenopausal women. Diabetes Care. 2012;34:2542–2544.
6. Erickson K, Patterson RE, Flatt SW, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol. 2011;29:54–60.
7. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: A systematic review and meta-analysis. J Clin Oncol. 2011;29:40–46.
8. Patterson RE, Flatt SW, Saquib N, et al. Medical comorbidities predict mortality in women with a history of early stage breast cancer. Breast Cancer Res Treat. 2010;122:859–865.
9. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol. 2002;20:42–51.
10. Irwin ML, Duggan C, Wang CY, et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: The Health, Eating, Activity and Lifestyle Study. J Clin Oncol. 2011;29:47–53.
11. Duggan C, Irwin ML, Xiao L, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol. 2011;29:32–39.
12. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy—A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:17–30.
13. Goodwin PJ, Pritchard KI, Ennis M, et al. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 2008;8:501–505.
14. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269–10273.
15. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and reduces cell cycle arrest in vitro. Cell Cycle. 2009;8:909–915.
16. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304–1305.
17. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:1451–1461.
18. Bo S, Ciccone G, Rosato R, et al. Cancer mortality reduction and metformin: A retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab. 2012;14:23–29.
19. Bodmer M, Meier C, Krähenbühl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33:1304–1308.
20. Bosco JL, Antonsen S, Sørensen HT, et al. Metformin and incident breast cancer among diabetic women: A population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev. 2011;20:101–111.
21. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population-based follow-up study. Diabetes Care. 2012;35:119–124.
22. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620–1625.
23. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–1777.
24. Berstein LM, Boyarkina MP, Tsyrlina EV, et al. More favorable progesterone receptor phenotype of breast cancer in diabetes treated with metformin. Med Oncol. 2011;28:1260–1263.
25. Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML, Draznin B. Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Biol Chem. 2001;276:38023–8.
26. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8:2031–40.
27. Fontana SA, Baumann LC, Helberg C, et al. The delivery of preventive services in primary care practices according to chronic disease status. Am J Public Health. 1997;87:1190–1196.
28. Beckman TJ, Cuddihy RM, Scheitel SM, et al. Screening mammogram utilization in women with diabetes. Diabetes Care. 2001;24:2049–2053.
29. Jiménez-Garcia R, Hernandez-Barrera V, Carrasco-Garrido P, et al. Prevalence and predictors of breast and cervical cancer screening among Spanish women with diabetes. Diabetes Care. 2009;32:1470–1472.
30. Marshall JG, Cowell JM, Campbell ES, et al. Regional variations in cancer screening rates found in women with diabetes. Nurs Res. 2010;59:34–41.
31. Fitch MI, Greenberg M, Levstein L, et al. Health promotion and early detection of cancer in older adults: Needs assessment for program development. Cancer Nurs. 1997;20:381–388.
32. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat. 2011;128:783–794.
33. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol. 2010;11:174–183.
34. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27:3297–3302.
35. He X, Esteva FJ, Ensor J, et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. [epub ahead of print on November 22, 2011]
36. Bayraktar S, Hernadez-Aya LF, Lei X, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012;118:1202–1211.